Together, these observations, coupled with anti-IL-11/anti-IL-11RA antibodies currently being under early stage clinical development for idiopathic pulmonary diseases (95), may provide the background for future clinical trials testing such novel therapeutic class of drugs in progressive CKD added on top of standard of care with optimally dosed renin-angiotensin-aldosterone system blockers and sodium-glucose cotransporter-2 inhibitors. Here, IL11 is linked to chronic kidney disease.